Free Access
Med Sci (Paris)
Volume 31, Number 12, Décembre 2015
Page(s) 1075 - 1077
Section Nouvelles
Published online 16 December 2015
  1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013 ; 19 : 850–858. [CrossRef] [PubMed] [Google Scholar]
  2. Zona L, Turek M, Baumert TF, Zeisel MB. Hepatitis C virus internalization. Virologie 2013 ; 17 : 401–413. [Google Scholar]
  3. Harris HJ, Farquhar MJ, Mee CJ, et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 2008 ; 82 : 5007–5020. [CrossRef] [PubMed] [Google Scholar]
  4. Zona L, Lupberger J, Sidahmed-Adrar N, et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 2013 ; 13 : 302–313. [CrossRef] [PubMed] [Google Scholar]
  5. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011 ; 17 : 589–595. [CrossRef] [PubMed] [Google Scholar]
  6. Sainz B, Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012 ; 18 : 281–285. [CrossRef] [PubMed] [Google Scholar]
  7. Meuleman P, Hesselgesser J, Paulson M, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008 ; 48 : 1761–1768. [CrossRef] [PubMed] [Google Scholar]
  8. Lacek K, Vercauteren K, Grzyb K, et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 2012 ; 57 : 17–23. [CrossRef] [PubMed] [Google Scholar]
  9. Vercauteren K, Van Den Eede N, Mesalam AA, et al. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology 2014 ; 60 : 1508–1518. [CrossRef] [PubMed] [Google Scholar]
  10. Fofana I, Krieger SE, Grunert F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010 ; 139 : 953–964. e4. [CrossRef] [PubMed] [Google Scholar]
  11. Mailly L, Xiao F, Lupberger J, et al. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 2015 ; 33 : 549–554. [CrossRef] [PubMed] [Google Scholar]
  12. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998 ; 282 : 103–107. [CrossRef] [PubMed] [Google Scholar]
  13. Xiao F, Fofana I, Thumann C, et al. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 2015 ; 64 : 483–494. [CrossRef] [PubMed] [Google Scholar]
  14. Lu RY, Yang WX, Hu YJ. The role of epithelial tight junctions involved in pathogen infections. Mol Biol Rep 2014 ; 41 : 6591–6610. [CrossRef] [PubMed] [Google Scholar]
  15. Uprichard SL, Sainz B, Jr.. Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment. Gut 2015 ; 64 : 690–691. [CrossRef] [PubMed] [Google Scholar]
  16. Ray K. Hepatitis: Tightening the grip on clearing HCV infection. Nat Rev Gastroenterol Hepatol 2015 ; 12 : 249. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.